Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME8FZ9)

• Drug Name: Methoxsalen Drug Info
• Synonyms: Ammodin; Ammoidin; Deltasoralen; Dermox; Geroxalen; Meladinin; Meladinina; Meladinine; Meladoxen; Meloxine; Methoxalen; Methoxaten; Oxoralen; Oxsoralen; Oxypsoralen; Puvalen; Puvamet; Ultramop; Uvadex; XANTHOTOXIN; Xanthotoxine; Zanthotoxin; Boehringer Ingelheim Brand of Methoxsalen; Canderm Brand of Methoxsalen; Chinoin Brand of Methoxsalen; DB Brand of Methoxsalen; Delta Brand of Methoxsalen; Dermatech Brand of Methoxsalen; Galderma Brand of Methoxsalen; Methoxa Dome; Methoxsalen Canderm Brand; Methoxsalen Chinoin Brand; Methoxsalen Delta Brand; Methoxsalen Dermatech Brand; Methoxsalen plus ultraviolet radiation; Mex America Brand of Methoxsalen; Oxsoralen Ul tra; Oxsoralen Ultra; Oxsoralen lotion; Sanofi Synthelabo Brand of Methoxsalen; Ultra Mop; Ultramop Lotion; ICN Brand 1 of Methoxsalen; ICN Brand 2 of Methoxsalen; ICN Brand 3 of Methoxsalen; X0009; An 8-methoxyfurocoumarin; Meladinin (VAN); Methoxa-Dome; Methoxsalen Mex-America Brand; Methoxsalen Sanofi-Synthelabo Brand; Methoxsalen [BAN:JAN]; Methoxsalen with ultra-violet A theraphy; Mex-America Brand of Methoxsalen; New-Meladinin; O-methylxanthotoxol; OXSORALEN (TN); Oxsoralen (TN); Oxsoralen-ultra; Proralone-mop; Psoralen-mop; Psoralon-MOP; Sanofi-Synthelabo Brand of Methoxsalen; Methoxsalen (JP15/USP); Methoxy-8-psoralen; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone; 5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone; 6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone; 7-Furocoumarin; 8 Methoxypsoralen; 8-METHOXYPSORALEN + UVA (SEE ALSO C55903); 8-MOP; 8-Methoxy; 8-Methoxy(furano-3'.2':6.7-coumarin); 8-Methoxy-(furano-3'.2':6.7-coumarin); 8-Methoxy-2',3',6,7-furocoumarin; 8-Methoxy-4',5',6,7-furocoumarin; 8-Methoxy-4',5':6,7-furocoumarin; 8-Methoxy-[furano-3'.2':6.7-coumarin]; 8-Methoxyfuranocoumarin; 8-Methoxypsoralen; 8-Methoxypsoralen with ultraviolet A therapy; 8-Methoxypsoralene; 8-methoxyfuranocoumarins; 8-methoxyfurocoumarins; 8MO; 8MOP; 9-(methyloxy)-7H-furo[3,2-g]chromen-7-one; 9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one; 9-Methoxy-7H-furo(3,2-g)benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one; 9-Methoxy-7H-furo[3,2-g]chromen-7-one; 9-Methoxyfuro(3,2-g)chromen-7-one; 9-Methoxyfuro[3,2-g][1]benzopyran-7-one; 9-Methoxypsoralen; 9-metho xy-7H-furo(3,2-g)benzopyran-7-one; 9-methoxyfuro[3,2-g]chromen-7-one

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous T-cell lymphoma	2B01	Approved	[1]
Primary cutaneous T-cell lymphoma		Approved	[2]
Psoriasis vulgaris	EA90	Approved	[1]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 4114
  ChEBI ID: CHEBI:18358
  CAS Number: CAS 298-81-7
  TTD Drug ID: DME8FZ9
  VARIDT Drug ID: DR00920
  INTEDE Drug ID: DR1047

Molecule-Related Drug Atlas

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[9]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[10]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[11]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[12]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[13]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[15]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[16]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[10]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[17]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[34]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[35]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[36]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[37]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[38]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[38]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[39]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[40]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[41]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[42]

Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[18]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[19]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[20]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[13]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[19]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Metronidazole	DMTIVEN	Abscess		Approved	[22]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[23]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[24]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Tegafur	DM31ZQM	Solid tumour/cancer	2A00-2F9Z	Approved	[25]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[26]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[27]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[28]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[12]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[29]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[30]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[31]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[32]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[33]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[43]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[43]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[43]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[44]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[45]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[46]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[47]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[48]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[49]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[50]

Drug(s) Affected By Cocaine esterase (CES2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[51]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]
Dextropropoxyphene	DM23HCX	Pain	MG30-MG3Z	Approved	[53]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[54]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[55]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[56]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[58]
Cantharidin	DMBP5N3	Molluscum contagiosum infection	1E76	Approved	[59]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[60]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[60]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[61]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[62]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[63]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[60]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[60]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[60]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[64]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[65]

Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[67]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[68]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[69]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[70]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[71]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[44]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[38]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[72]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[73]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[35]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[74]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[38]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[37]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[44]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[75]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[38]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[76]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[37]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[38]

Drug(s) Affected By Class E basic helix-loop-helix protein 40 (BHLHE40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[77]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[55]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[78]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[79]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[80]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[81]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[82]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[83]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[84]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[85]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[86]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[87]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[88]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[89]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[90]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[91]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[92]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[93]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[94]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]

Drug(s) Affected By ATP-binding cassette sub-family C member 3 (ABCC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[96]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[97]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[98]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[8]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[99]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[100]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[101]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[102]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[103]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[104]

Drug(s) Affected By Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[105]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[106]
Fructose	DM43AN2	Vomiting	MD90	Approved	[50]
Ketoprofen	DMRKXPT	Bursitis		Approved	[50]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[107]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[108]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[109]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[110]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[111]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[113]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[114]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[115]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[116]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[117]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[118]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[119]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[120]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[121]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[122]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[123]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[124]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[125]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[126]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[127]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[128]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[129]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[130]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[131]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[132]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[133]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[134]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[135]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[136]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[137]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[138]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[139]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[140]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[141]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[139]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[142]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[143]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[144]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[145]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[50]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[146]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[147]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[148]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[108]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[149]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[150]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[151]
Methysergide	DM1EF73	Migraine	8A80	Approved	[152]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[153]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[54]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[152]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[55]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[154]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[155]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[156]

Drug(s) Affected By Cytochrome P450 7A1 (CYP7A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[8]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[153]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[54]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[157]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[158]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[128]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[160]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[161]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[157]

Drug(s) Affected By Multidrug resistance-associated protein 1 (ABCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[162]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[163]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[164]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[165]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[166]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[167]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[168]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[169]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[170]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[170]

Drug(s) Affected By Histidine ammonia-lyase (HAL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[55]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[171]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[172]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[57]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[173]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[174]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[28]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[57]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[175]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[176]

Drug(s) Affected By Caspase-9 (CASP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[177]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[178]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[146]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[148]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[179]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[180]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[89]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[181]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[182]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[183]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[142]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[184]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[146]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[147]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[185]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[179]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[186]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[187]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[188]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[189]

Drug(s) Affected By Caspase-8 (CASP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[190]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[191]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[192]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[193]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[194]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[195]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[89]
Selenium	DM25CGV	N. A.	N. A.	Approved	[196]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[182]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[114]

Drug(s) Affected By Nuclear receptor subfamily 0 group B member 2 (NR0B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[8]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[197]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[198]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[199]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[153]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[197]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[200]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[201]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[55]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[197]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[124]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[202]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[203]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[204]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[205]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[206]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[207]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[208]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[209]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[210]

Drug(s) Affected By ATP-binding cassette sub-family C member 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[211]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[212]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[213]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[214]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[164]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[215]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[216]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[168]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[96]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[217]

Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[218]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[218]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[219]
Sunitinib	DMCBJSR	Acute undifferentiated leukemia		Approved	[50]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[220]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[221]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[222]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[223]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[224]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[225]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytochrome P450 2A6 (CYP2A6)	TTAQ6ZW	CP2A6_HUMAN	Binder	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[6]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[6]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Gene/Protein Processing	[7]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Gene/Protein Processing	[8]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[7]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[6]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Gene/Protein Processing	[7]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Gene/Protein Processing	[6]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Gene/Protein Processing	[6]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[6]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009048.
• [2] Methoxsalen FDA Label
• [3] Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol. 1984 May;120(5):662-9.
• [4] Photochemotherapeutic agent 8-methoxypsoralen induces cytochrome P450 3A4 and carboxylesterase HCE2: evidence on an involvement of the pregnane X receptor. Toxicol Sci. 2007 Jan;95(1):13-22.
• [5] Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999 Oct;48(4):528-35.
• [6] Down regulation of differentiated embryonic chondrocytes 1 (DEC1) is involved in 8-methoxypsoralen-induced apoptosis in HepG2 cells. Toxicology. 2012 Nov 15;301(1-3):58-65. doi: 10.1016/j.tox.2012.06.022. Epub 2012 Jul 11.
• [7] ABC-transporter blockage mediated by xanthotoxin and bergapten is the major pathway for chemosensitization of multidrug-resistant cancer cells. Toxicol Appl Pharmacol. 2017 Dec 15;337:22-29. doi: 10.1016/j.taap.2017.10.018. Epub 2017 Oct 25.
• [8] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [9] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [10] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [11] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [12] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [13] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [14] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [15] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [16] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [17] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [18] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [19] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [20] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [21] Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
• [22] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [23] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [24] CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
• [25] Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos. 2005 Sep;33(9):1361-6. doi: 10.1124/dmd.105.004796. Epub 2005 Jun 24.
• [26] Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res. 2001 May;92(5):524-8. doi: 10.1111/j.1349-7006.2001.tb01125.x.
• [27] CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In Vitro. 2011 Jun;25(4):922-9.
• [28] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [29] Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
• [30] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [31] Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009 Nov;39(11):795-802. doi: 10.3109/00498250903171395.
• [32] A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun. 2001 Mar 2;281(3):810-4. doi: 10.1006/bbrc.2001.4422.
• [33] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [34] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [35] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [36] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [37] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [38] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [39] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [40] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [41] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [42] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [43] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [44] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [45] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [46] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [47] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [48] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [49] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [50] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [51] Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos. 2000 Feb;28(2):186-91.
• [52] Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biol Ther. 2006 Nov;5(11):1450-6.
• [53] Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp Ther. 1999 Jul;290(1):314-8.
• [54] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [55] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [56] Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact. 2013 Mar 25;203(1):226-30.
• [57] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [58] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [59] Hepatoxicity mechanism of cantharidin-induced liver LO2 cells by LC-MS metabolomics combined traditional approaches. Toxicol Lett. 2020 Oct 15;333:49-61. doi: 10.1016/j.toxlet.2020.07.024. Epub 2020 Jul 26.
• [60] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [61] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [62] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [63] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [64] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [65] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [66] Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
• [67] Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
• [68] Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
• [69] Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
• [70] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [71] Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
• [72] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
• [73] Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
• [74] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [75] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [76] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
• [77] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [78] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [79] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [80] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [81] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [82] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [83] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [84] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [85] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [86] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [87] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [88] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [89] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [90] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [91] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [92] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [93] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [94] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [95] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [96] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [97] Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol. 2009 Apr 15;77(8):1410-7.
• [98] Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005 May 14;11(18):2748-53. doi: 10.3748/wjg.v11.i18.2748.
• [99] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [100] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [101] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [102] Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):229-34. doi: 10.1016/j.jsbmb.2005.03.004.
• [103] Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
• [104] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [105] Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
• [106] A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
• [107] CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
• [108] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [109] Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
• [110] Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
• [111] Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
• [112] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [113] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [114] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [115] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [116] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [117] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [118] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [119] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [120] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [121] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [122] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [123] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [124] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [125] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [126] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [127] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [128] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [129] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [130] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [131] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [132] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [133] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [134] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [135] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [136] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [137] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [138] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [139] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [140] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [141] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [142] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [143] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [144] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [145] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [146] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [147] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [148] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [149] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [150] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [151] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [152] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [153] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [154] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [155] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [156] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [157] The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem. 2004 Mar 5;279(10):8856-61. doi: 10.1074/jbc.M306422200. Epub 2003 Dec 18.
• [158] The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
• [159] Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology. 2011 Feb;53(2):548-57. doi: 10.1002/hep.24047. Epub 2010 Dec 10.
• [160] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [161] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [162] Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines. Toxicol Lett. 2015 Jun 15;235(3):189-98. doi: 10.1016/j.toxlet.2015.04.005. Epub 2015 Apr 9.
• [163] Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
• [164] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [165] Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46.
• [166] Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
• [167] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [168] Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
• [169] Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology. 2007 Dec;12(6):511-7. doi: 10.1080/10245330701562535.
• [170] Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002 Jun 19;521(1-3):211-3. doi: 10.1016/s0014-5793(02)02816-8.
• [171] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [172] Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol. 2003 May;85(1):1-8. doi: 10.1016/s0960-0760(03)00142-0.
• [173] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [174] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [175] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [176] Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-beta-dependent mechanisms. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4558-66.
• [177] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [178] Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
• [179] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [180] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [181] Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
• [182] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [183] Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
• [184] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [185] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [186] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [187] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [188] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [189] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [190] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [191] Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.
• [192] Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
• [193] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [194] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [195] Melatonin enhances hydrogen peroxide-induced apoptosis in human promyelocytic leukaemia HL-60 cells. Mol Cell Biochem. 2011 Jul;353(1-2):167-76. doi: 10.1007/s11010-011-0783-8. Epub 2011 Mar 23.
• [196] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [197] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [198] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [199] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [200] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [201] Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One. 2012;7(4):e35895. doi: 10.1371/journal.pone.0035895. Epub 2012 Apr 23.
• [202] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [203] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [204] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [205] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [206] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [207] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [208] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [209] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [210] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [211] Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics. 2011 Dec;21(12):884-93. doi: 10.1097/FPC.0b013e32834d672b.
• [212] Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther. 2004 Jan;308(1):260-7. doi: 10.1124/jpet.103.057729. Epub 2003 Oct 20.
• [213] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [214] Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
• [215] In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
• [216] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [217] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [218] Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
• [219] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
• [220] ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
• [221] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [222] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [223] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [224] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [225] Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.